Related Experiment Video
Updated: Apr 10, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
Benjamin D Ferguson1, Yi-Hung Carol Tan2, Rajani S Kanteti2
1Department of Surgery, University of Chicago, Chicago, Illinois, United States of America.
Abstract:
Lung cancer outcomes remain poor despite the identification of several potential therapeutic targets. The EPHB4 receptor tyrosine kinase (RTK) has recently emerged as an oncogenic factor in many cancers, including lung cancer. Mutations of EPHB4 in lung cancers have previously been identified, though their significance remains unknown. Here, we report the identification of novel EPHB4 mutations that lead to putative structural alterations as well as increased cellular proliferation and motility. We also conducted a bioinformatic analysis of these mutations to demonstrate that they are mutually exclusive from other common RTK variants in lung cancer, that they correspond to analogous sites of other RTKs' variations in cancers, and that they are predicted to be oncogenic based on biochemical, evolutionary, and domain-function constraints. Finally, we show that EPHB4 mutations can induce broad changes in the kinome signature of lung cancer cells. Taken together, these data illuminate the role of EPHB4 in lung cancer and further identify EPHB4 as a potentially important therapeutic target.
Insights
New lung cancer mutations in the EPHB4 receptor tyrosine kinase (RTK) drive cell growth and movement. These findings highlight EPHB4 as a promising new therapeutic target for improving lung cancer outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer has poor outcomes despite targeted therapies.
- The EPHB4 receptor tyrosine kinase (RTK) is implicated in various cancers.
- The role of EPHB4 mutations in lung cancer is not well understood.
Purpose of the Study:
- Identify novel EPHB4 mutations in lung cancer.
- Investigate the functional and clinical significance of these mutations.
- Evaluate EPHB4 as a potential therapeutic target for lung cancer.
Main Methods:
- Identification and characterization of novel EPHB4 mutations.
- Bioinformatic analysis of mutation data.
- Assessment of cellular proliferation and motility.
- Kinome profiling of lung cancer cells.
Main Results:
- Novel EPHB4 mutations were identified, causing structural changes.
- These mutations increased lung cancer cell proliferation and motility.
- Bioinformatic analysis confirmed mutations are oncogenic and mutually exclusive with other RTK variants.
- EPHB4 mutations altered the kinome signature of lung cancer cells.
Conclusions:
- EPHB4 mutations play a significant role in lung cancer development.
- EPHB4 is a potential therapeutic target for lung cancer treatment.
- Further research into EPHB4-targeted therapies is warranted.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Tyrosine Kinases
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
PI3K/mTOR/AKT Signaling Pathway